5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Device Type, Therapeutic Application, and Sales Channel
The China Drug Delivery Devices market studied was anticipated to grow at a CAGR of 9.3%, during the forecast period. The major factors attributing to the growth of the China drug delivery devices market are growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self injectors and growth of the biologic market, leading to increased demand for drug delivery devices. The increasing prevalence of chronic diseases has led to increased use of drug delivery devices in common, particularly disposable syringes. Many deaths from chronic diseases could be linked to cancer, heart disease, overweight, and diabetes.
As per The State Council Information Office of the People’s Republic of China, each year doctors diagnose 260 million people with chronic diseases. Chronic illness accounts for 85 percent of China's fatalities each year. The diseases which contribute for most of the deaths are: cancer (27.79%), cerebrovascular disorder (20.22%) and heart disease (21.3%). This is anticipated to most affect the market and increase in population is one of the factor impacting the market as population growth is considered to be the country's most significant factor. The other factors helping the growth of the drug delivery devices market are the increasing technological advancement is also one of the key factor fueling the market growth during the forecast period.
Drug delivery systems are the medical equipment and devices used to deliver the medicines to human bodies and different systems. These are specifically designed to administer the specific drugs in accordance with the different techniques of administration. Such tools are used for therapeutic procedures and the whole process of healing.
|By Device Type|
|By Therapeutic Application|
|By Sales Channel|
Report scope can be customized per your requirements. Click here.
There have been boundless innovations and developments in self-injectable devices driving the growth of the market in the country. The other major advantages associated with self-injectable injections are that they are found to be of convenient usage at low cost. These are the most adaptable devices, which have high precision of drug delivery, and are easy to use. In addition to this, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. Nevertheless, the advantages of self-injectable injections and increasing awareness of self-administration have helped in driving the overall market growth, during the forecast period.
To understand key trends, Download Sample Report
The China drug delivery devices market is competitive and consists of several players. In terms of market share, few of the major players are currently dominating the market and some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions in the country. Some of the companies which are currently domianting the market are Gerresheimer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, and Teva Pharmaceutical Industries Ltd.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Prevalence of Chronic Diseases
4.2.2 Advancement in Technology
4.3 Market Restraints
4.3.1 The High Cost of Development
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Device Type
220.127.116.11 Conventional Drug Delivery Devices
18.104.22.168 Self-Injectable Drug Delivery Devices
22.214.171.124.1 Prefilled Syringes
126.96.36.199.2 Auto Injectors
5.2 By Therapeutic Application
5.2.3 Autoimmune Disorder
5.2.4 Pulmonary Disease
5.3 By Sales Channel
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Gerresheimer AG
6.1.2 Pfizer Inc.
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Teva Pharmaceutical Industries Ltd.
6.1.6 Merck & Co., Inc.
6.1.7 Novartis International AG
6.1.8 Sanofi S.A.
6.1.9 GlaxoSmithKline plc
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments